Dr. Rhonda Patrick

It probably varies depending on the person and what their side effects and stuff are, but eating the protein and then like, are they absorbing all the protein?

I don't know if anyone's even looked at that, but that's interesting.

They're certainly not eating enough protein.

Yeah.

There's another interesting...

Yeah, that was my next question for you.

alzheimer's disease now and in you have to wonder like is is this a is there a direct effect of you know agonizing these glp-1 receptors on different tissues or is this just an indirect effect of weight loss and improved metabolic health right yeah yeah so i i don't know but we what i can speak to is our unpublished results right now in muscle cells we're treating them with varying doses of semaglutide at the higher doses

Okay.

Well, then this gets back to the microdosing.

And this is kind of, you know, I feel like you were talking about microdosing GLP-1 agonists for a very different reason than I'm going to ask you about now.

And you're talking about appetite regulation.

And I think that's...

It's super interesting, particularly for people who don't have real good control of their appetite or perhaps their I mean, who know their hormones are out of whack.

Right.

But there is now this sort of growing budding interest amongst, you know, many people about this.

potential GLP-1 agonist being a longevity drug because of these different, you know, outcome studies that have been observational in nature, right?

We're looking at correlation here.

But the question is, well, like, some people are now sort of starting to whisper about, we think now maybe these drugs are actually affecting, they're actually pro-longevity.

And so microdosing, you know, these drugs in the ranges that you were discussing earlier might be a way of

Getting the benefits.